Stock IMU IMUGENE LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

All News Imugene Limited

Equities

IMU

AU000000IMU9

Market Closed - Australian S.E.
Other stock markets
 02:10:31 2024-05-06 am EDT 		5-day change 1st Jan Change
0.077 AUD -6.10% Intraday chart for Imugene Limited -2.53% -30.00%
Apr. 16 Imugene Signs Deal to Sell Manufacturing Facility For $6 Million MT
Apr. 16 Kincell Bio, LLC signed an asset purchase agreement to acquire North Carolina manufacturing facility from Imugene Limited for $6 million. CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Imugene partners with Kincell Bio; selling cell therapy manufacturing facility for $6 million
AQ
Imugene Signs Deal to Sell Manufacturing Facility For $6 Million
MT
Kincell Bio, LLC signed an asset purchase agreement to acquire North Carolina manufacturing facility from Imugene Limited for $6 million.
CI
Bile Tract Cancer expansion study opens following clearance of Imugene’s MAST trial high dose cohort
AQ
Imugene Limited Announce Enrolment Opened for Its Expansion Study in Bile Tract Cancer (Cholangiocarcinoma) Patients
CI
Imugene opens enrolment for Bile Tract Cancer expansion study
AQ
Imugene Commences Enrolment for Cholangiocarcinoma Expansion Study
MT
Imugene's oncolytic virotherapy VAXINIA and B cell immunotherapy HER-Vaxx featured at the AACR Annual Meeting 2024
AQ
Imugene Secures Patent for Oncolytic Virotherapy CF33 in China
MT
Arovella Therapeutics' ALA-101-onCARlytics Collaboration with Imugene Ends; Shares Down 12%
MT
Imugene progresses onCARlytics solid tumour trial to combination arm
AQ
Phase 1 onCARlytics solid tumour trial advances to combination arm treatment
AQ
Imugene Limited Announces Phase 1 onCARlytics Solid Tumour Trial Advances to Combination Arm Treatment
CI
Imugene's Phase 1 onCARlytics Trial to Commence Combination Arm Treatment
MT
Imugene Widens Per-Share Loss in H1 FY24 to AU$0.01 on Higher General, R&D Spending
MT
Imugene Reports H1 FY24 Loss Widens as Expenses Grow
MT
Imugene Limited Reports Earnings Results for the Half Year Ended December 31, 2023
CI
Imugene Highlights Recent Achievements and Looks Ahead to Key Upcoming Immuno-oncology Catalysts
AQ
Imugene doses first patient in intravenous monotherapy arm of Phase 1 clinical trial
AQ
Imugene’s Phase 1 onCARlytics Trial Doses First Patient in Intravenous Monotherapy Arm
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. IMU Stock
  4. News Imugene Limited
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW